Vertex Pharmaceuticals 2025 JPM Presentation PDF.pdf

1、J.P.MORGAN HEALTHCARE CONFERENCEJANUARY 2025RESHMA KEWALRAMANI,M.D.CEO AND PRESIDENT2025 Vertex Pharmaceuticals IncorporatedSAFE HARBOR STATEMENT&NON-GAAP FINANCIAL MEASURESThis presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,includ

2、ing,without limitation,the information provided regarding future financial and operating performance and statements regarding(i)expectations,development plans and timelines for the companys products,product candidates and pipeline programs,including expectations that we are on track to complete five

3、 launches in five years,that we have pipeline diversification across diseases and geographies with pipeline opportunities across multiple multi-billion dollar markets,and the anticipated benefits of new products and regarding relevant patient populations,(ii)expectations for uptake of and expanded a

4、ccess to our products,(iii)expectations for sustained and profitable growth with respect to our CF medicines,including expectations that we will treat younger patients,patients will live longer,we will reach additional geographies,and expectations to attain carrier levels of CFTR function for all pa

5、tients,(iv)our beliefs regarding the U.S.commercial launch of ALYFTREK,and expectations regarding global regulatory approvals and global launches for ALYFTREK,(v)plans to reach the last 5,000 CF patients with mRNA therapy,including expectations that we will complete the MAD portion of the Phase 1/2

6、study in VX-522 and share data in the first half of 2025,(vi)expectations for CASGEVY,including with respect to its commercial potential,reaching more patients across geographies,expanding manufacturing to support global demand,advancing studies in younger age groups,and the potential to improve con